Literature DB >> 27717250

Right patient, right treatment, right time: biosignatures and precision medicine in depression.

Madhukar H Trivedi1.   

Abstract

Entities:  

Year:  2016        PMID： 27717250      PMCID： PMC5032506          DOI： 10.1002/wps.20371

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  10 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  Modeling predictors, moderators and mediators of treatment outcome and resistance in depression.

Authors:  Madhukar H Trivedi
Journal:  Biol Psychiatry       Date:  2013-07-01       Impact factor: 13.382

Review 3.  The dexamethasone suppression test in patients with mood disorders.

Authors:  A J Rush; D E Giles; M A Schlesser; P J Orsulak; C R Parker; J E Weissenburger; G T Crowley; M Khatami; N Vasavada
Journal:  J Clin Psychiatry       Date:  1996-10       Impact factor: 4.384

4.  Toward discovery science of human brain function.

Authors:  Bharat B Biswal; Maarten Mennes; Xi-Nian Zuo; Suril Gohel; Clare Kelly; Steve M Smith; Christian F Beckmann; Jonathan S Adelstein; Randy L Buckner; Stan Colcombe; Anne-Marie Dogonowski; Monique Ernst; Damien Fair; Michelle Hampson; Matthew J Hoptman; James S Hyde; Vesa J Kiviniemi; Rolf Kötter; Shi-Jiang Li; Ching-Po Lin; Mark J Lowe; Clare Mackay; David J Madden; Kristoffer H Madsen; Daniel S Margulies; Helen S Mayberg; Katie McMahon; Christopher S Monk; Stewart H Mostofsky; Bonnie J Nagel; James J Pekar; Scott J Peltier; Steven E Petersen; Valentin Riedl; Serge A R B Rombouts; Bart Rypma; Bradley L Schlaggar; Sein Schmidt; Rachael D Seidler; Greg J Siegle; Christian Sorg; Gao-Jun Teng; Juha Veijola; Arno Villringer; Martin Walter; Lihong Wang; Xu-Chu Weng; Susan Whitfield-Gabrieli; Peter Williamson; Christian Windischberger; Yu-Feng Zang; Hong-Ying Zhang; F Xavier Castellanos; Michael P Milham
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-22       Impact factor: 11.205

Review 5.  Translating genomics for precision cancer medicine.

Authors:  Sameek Roychowdhury; Arul M Chinnaiyan
Journal:  Annu Rev Genomics Hum Genet       Date:  2014       Impact factor: 8.929

6.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

7.  Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.

Authors:  Madhukar H Trivedi; Patrick J McGrath; Maurizio Fava; Ramin V Parsey; Benji T Kurian; Mary L Phillips; Maria A Oquendo; Gerard Bruder; Diego Pizzagalli; Marisa Toups; Crystal Cooper; Phil Adams; Sarah Weyandt; David W Morris; Bruce D Grannemann; R Todd Ogden; Randy Buckner; Melvin McInnis; Helena C Kraemer; Eva Petkova; Thomas J Carmody; Myrna M Weissman
Journal:  J Psychiatr Res       Date:  2016-03-15       Impact factor: 4.791

8.  Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?

Authors:  S Kapur; A G Phillips; T R Insel
Journal:  Mol Psychiatry       Date:  2012-08-07       Impact factor: 15.992

9.  The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.

Authors:  J M Biernacka; K Sangkuhl; G Jenkins; R M Whaley; P Barman; A Batzler; R B Altman; V Arolt; J Brockmöller; C H Chen; K Domschke; D K Hall-Flavin; C J Hong; A Illi; Y Ji; O Kampman; T Kinoshita; E Leinonen; Y J Liou; T Mushiroda; S Nonen; M K Skime; L Wang; B T Baune; M Kato; Y L Liu; V Praphanphoj; J C Stingl; S J Tsai; M Kubo; T E Klein; R Weinshilboum
Journal:  Transl Psychiatry       Date:  2015-04-21       Impact factor: 6.222

10.  Quest for biomarkers of treatment-resistant depression: shifting the paradigm toward risk.

Authors:  Donald F Smith
Journal:  Front Psychiatry       Date:  2013-06-18       Impact factor: 4.157
  10 in total
  5 in total

Review 1.  Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools.

Authors:  Chad A Bousman; Malcolm Forbes; Mahesh Jayaram; Harris Eyre; Charles F Reynolds; Michael Berk; Malcolm Hopwood; Chee Ng
Journal:  BMC Psychiatry       Date:  2017-02-08       Impact factor: 3.630

Review 2.  Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.

Authors:  Manish K Jha; Madhukar H Trivedi
Journal:  Int J Mol Sci       Date:  2018-01-12       Impact factor: 5.923

Review 3.  Gene expression studies in Depression development and treatment: an overview of the underlying molecular mechanisms and biological processes to identify biomarkers.

Authors:  Nicole Mariani; Nadia Cattane; Carmine Pariante; Annamaria Cattaneo
Journal:  Transl Psychiatry       Date:  2021-06-08       Impact factor: 6.222

4.  Key considerations in the pharmacological management of treatment-resistant depression.

Authors:  Mani Yavi; Ioline D Henter; Lawrence T Park; Carlos Zarate
Journal:  Expert Opin Pharmacother       Date:  2021-07-21       Impact factor: 3.889

5.  Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination.

Authors:  Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Madhukar H Trivedi
Journal:  Int J Neuropsychopharmacol       Date:  2017-11-01       Impact factor: 5.176
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.